Literature DB >> 11866274

Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins.

Masanobu Kayazawa1, Osamu Saitoh, Keishi Kojima, Ken Nakagawa, Seigou Tanaka, Kazue Tabata, Ryoichi Matsuse, Kazuo Uchida, Masahiro Hoshimoto, Ichiro Hirata, Ken-ichi Katsu.   

Abstract

OBJECTIVES: We investigated which neutrophil-derived proteins in whole gut lavage fluid (WGLF) most accurately reflect disease activity in inflammatory bowel disease.
METHODS: WGLF was obtained from patients undergoing whole gut lavage as a bowel preparation for colonoscopy. Twenty-seven patients with ulcerative colitis (UC), 23 patients with Crohn's disease (CD), and 35 control subjects were examined. The concentrations of lactoferrin, polymorphonuclear neutrophil elastase (PMN-E), myeloperoxidase, and lysozyme in WGLF were measured by ELISA. For the assessment of stability, WGLF samples were stored at 37 degrees C for various periods.
RESULTS: In UC, the concentrations of lactoferrin, myeloperoxidase, and lysozyme in WGLF had good correlations with colonoscopic grading. Zero, 12, five, and 10 of 28 samples from active UC patients showed normal concentrations of lactoferrin, PMN-E, myeloperoxidase, and lysozyme, respectively. In CD, the concentrations of lactoferrin and myeloperoxidase had good correlations with the Crohn's disease activity index. Thirteen and seven of 36 samples from inactive CD patients (Crohn's disease activity index < or = 150) showed high concentrations of lactoferrin and myeloperoxidase, respectively. Most of them (11/13, 6/7) were found to have ulceration by colonoscopy or small bowel x-ray. The ratio of the lactoferrin concentration in the WGLF supernatant to that in total WGLF was highest among these proteins in all disease groups and control subjects. Lactoferrin and myeloperoxidase showed good stability in WGLF, whereas PMN-E and lysozyme did not.
CONCLUSION: Lactoferrin is the most suitable of these proteins for use as a neutrophil-derived WGLF marker of intestinal inflammation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11866274     DOI: 10.1111/j.1572-0241.2002.05470.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  14 in total

Review 1.  Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis.

Authors:  Yan Wang; Fengyan Pei; Xingjuan Wang; Zhiyu Sun; Chengjin Hu; Hengli Dou
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Lactoferrin regulates an axis involving CD11b and CD49d integrins and the chemokines MIP-1α and MCP-1 in GM-CSF-treated human primary eosinophils.

Authors:  Colleen S Curran; Paul J Bertics
Journal:  J Interferon Cytokine Res       Date:  2012-06-25       Impact factor: 2.607

3.  Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease.

Authors:  Renata D'Incà; Elisabetta Dal Pont; Vincenza Di Leo; Antonio Ferronato; Walter Fries; Maria Grazia Vettorato; Diego Martines; Giacomo Carlo Sturniolo
Journal:  Int J Colorectal Dis       Date:  2006-07-13       Impact factor: 2.571

Review 4.  Current therapy of inflammatory bowel disease in children.

Authors:  Paul A Rufo; Athos Bousvaros
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Evaluation of fecal myeloperoxidase as a biomarker of disease activity and severity in ulcerative colitis.

Authors:  Ibrahim Masoodi; Rakesh Kochhar; Usha Dutta; Chetana Vaishnavi; K K Prasad; Kim Vaiphei; Shabnum Hussain; Kartar Singh
Journal:  Dig Dis Sci       Date:  2012-02-16       Impact factor: 3.199

Review 6.  Rectal effluent as a research tool.

Authors:  Jana M Rocker; Jack A DiPalma; Lewis K Pannell
Journal:  Dig Dis Sci       Date:  2014-09-02       Impact factor: 3.199

7.  Matrix metalloproteinase-7 (matrilysin) controls neutrophil egress by generating chemokine gradients.

Authors:  Mei Swee; Carole L Wilson; Ying Wang; John K McGuire; William C Parks
Journal:  J Leukoc Biol       Date:  2008-03-11       Impact factor: 4.962

8.  Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis.

Authors:  Jun-Ying Xiang; Qin Ouyang; Guo-Dong Li; Nan-Ping Xiao
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

9.  Fecal lactoferrin: a new parameter to monitor infliximab therapy.

Authors:  Stephan Buderus; James Boone; David Lyerly; Michael J Lentze
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

Review 10.  Non-invasive investigation in patients with inflammatory joint disease.

Authors:  Elisabetta Dal Pont; Renata D'Incà; Antonino Caruso; Giacomo-Carlo Sturniolo
Journal:  World J Gastroenterol       Date:  2009-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.